Cargando…
Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development
Glioblastoma (GBM) is an aggressive type of brain cancer with a poor prognosis for affected patients. The current line of treatment only gives the patients a survival time of on average 15 months. In this work, we use genome-scale metabolic models (GEMs) together with other systems biology tools to...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181968/ https://www.ncbi.nlm.nih.gov/pubmed/32362913 http://dx.doi.org/10.3389/fgene.2020.00381 |